Cargando…
Population Pharmacogenomics for Health Equity
Health equity means the opportunity for all people and populations to attain optimal health, and it requires intentional efforts to promote fairness in patient treatments and outcomes. Pharmacogenomic variants are genetic differences associated with how patients respond to medications, and their pre...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606908/ https://www.ncbi.nlm.nih.gov/pubmed/37895188 http://dx.doi.org/10.3390/genes14101840 |
_version_ | 1785127428260102144 |
---|---|
author | Jordan, I. King Sharma, Shivam Mariño-Ramírez, Leonardo |
author_facet | Jordan, I. King Sharma, Shivam Mariño-Ramírez, Leonardo |
author_sort | Jordan, I. King |
collection | PubMed |
description | Health equity means the opportunity for all people and populations to attain optimal health, and it requires intentional efforts to promote fairness in patient treatments and outcomes. Pharmacogenomic variants are genetic differences associated with how patients respond to medications, and their presence can inform treatment decisions. In this perspective, we contend that the study of pharmacogenomic variation within and between human populations—population pharmacogenomics—can and should be leveraged in support of health equity. The key observation in support of this contention is that racial and ethnic groups exhibit pronounced differences in the frequencies of numerous pharmacogenomic variants, with direct implications for clinical practice. The use of race and ethnicity to stratify pharmacogenomic risk provides a means to avoid potential harm caused by biases introduced when treatment regimens do not consider genetic differences between population groups, particularly when majority group genetic profiles are assumed to hold for minority groups. We focus on the mitigation of adverse drug reactions as an area where population pharmacogenomics can have a direct and immediate impact on public health. |
format | Online Article Text |
id | pubmed-10606908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106069082023-10-28 Population Pharmacogenomics for Health Equity Jordan, I. King Sharma, Shivam Mariño-Ramírez, Leonardo Genes (Basel) Perspective Health equity means the opportunity for all people and populations to attain optimal health, and it requires intentional efforts to promote fairness in patient treatments and outcomes. Pharmacogenomic variants are genetic differences associated with how patients respond to medications, and their presence can inform treatment decisions. In this perspective, we contend that the study of pharmacogenomic variation within and between human populations—population pharmacogenomics—can and should be leveraged in support of health equity. The key observation in support of this contention is that racial and ethnic groups exhibit pronounced differences in the frequencies of numerous pharmacogenomic variants, with direct implications for clinical practice. The use of race and ethnicity to stratify pharmacogenomic risk provides a means to avoid potential harm caused by biases introduced when treatment regimens do not consider genetic differences between population groups, particularly when majority group genetic profiles are assumed to hold for minority groups. We focus on the mitigation of adverse drug reactions as an area where population pharmacogenomics can have a direct and immediate impact on public health. MDPI 2023-09-22 /pmc/articles/PMC10606908/ /pubmed/37895188 http://dx.doi.org/10.3390/genes14101840 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Jordan, I. King Sharma, Shivam Mariño-Ramírez, Leonardo Population Pharmacogenomics for Health Equity |
title | Population Pharmacogenomics for Health Equity |
title_full | Population Pharmacogenomics for Health Equity |
title_fullStr | Population Pharmacogenomics for Health Equity |
title_full_unstemmed | Population Pharmacogenomics for Health Equity |
title_short | Population Pharmacogenomics for Health Equity |
title_sort | population pharmacogenomics for health equity |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606908/ https://www.ncbi.nlm.nih.gov/pubmed/37895188 http://dx.doi.org/10.3390/genes14101840 |
work_keys_str_mv | AT jordaniking populationpharmacogenomicsforhealthequity AT sharmashivam populationpharmacogenomicsforhealthequity AT marinoramirezleonardo populationpharmacogenomicsforhealthequity |